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Abstract: Patients with type 2 diabetes face an increased risk of macrovascular disease 
compared to those without. Signiﬁ  cant reductions in the risk of major cardiovascular events 
can be achieved with appropriate drug therapy, although patients with type 2 diabetes remain 
at increased risk compared with non-diabetics. The thiazolidinedione, pioglitazone, is known 
to offer multiple, potentially antiatherogenic, effects that may have a beneﬁ  cial impact on 
macrovascular outcomes, including long-term improvements in insulin resistance (associated 
with an increased rate of atherosclerosis) and improvement in the atherogenic lipid triad (low 
HDL-cholesterol, raised triglycerides, and a preponderance of small, dense LDL particles) that 
is observed in patients with type 2 diabetes. The recent PROspective pioglitAzone Clinical 
Trial In macroVascular Events (PROactive) study showed that pioglitazone can reduce the risk 
of secondary macrovascular events in a high-risk patient population with type 2 diabetes and 
established macrovascular disease. Here, we summarize the key results from the PROactive 
study and place them in context with other recent outcome trials in type 2 diabetes.
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Introduction
People with type 2 diabetes have a higher risk of macrovascular disease than those 
without diabetes (Haffner et al 1998; NCEP 2002; Juutilainen et al 2005; Idris et al 
2006). Furthermore, prognosis after a ﬁ  rst myocardial infarction (MI) or stroke is 
particularly poor in patients with type 2 diabetes (Miettinen et al 1998; Mukamal et al 
2001; Idris et al 2006). As such, type 2 diabetes is associated with excess mortality in 
all age groups, which is largely attributable to cardiovascular disease (CVD) (Roper 
et al 2001).
Outcome studies in patients with type 2 diabetes using antihypertensive agents, 
lipid-modifying drugs, and antiplatelet therapy show that signiﬁ  cant reductions in 
the risk of major CV events are possible with appropriate management. Furthermore, 
outcome studies with glucose-lowering agents show a trend towards reduced risk of 
macrovascular events (UKPDS33 1998). Nevertheless, these studies also show that 
excess risk remains in patients with type 2 diabetes relative to those without diabetes, 
despite contemporary interventions. This highlights the need for novel therapies for this 
high-risk group, especially those who also have established macrovascular disease.
Pioglitazone is an agonist for the peroxisome proliferator-activated receptor 
γ (PPARγ), which regulates multiple genes controlling carbohydrate and lipid 
metabolism and is licensed as a glucose-lowering agent for the treatment of type 2 
diabetes (Yki-Järvinen 2004). Pioglitazone has multiple, potentially antiatherogenic 
properties, including effects on insulin sensitivity, lipid proﬁ  les, inﬂ  ammatory 
markers, blood pressure, and components of the coagulation cascade that suggest it Vascular Health and Risk Management 2007:3(4) 356
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might have a beneﬁ  cial impact on macrovascular outcomes. 
This has been investigated in the PROspective pioglitAzone 
Clinical Trial In macroVascular Events (PROactive) study 
and ﬁ  nal results have been published recently. This study, 
in more than 5000 high-risk patients with type 2 diabetes 
and a history of macrovascular disease, investigated whether 
pioglitazone added to standard contemporary multifactorial 
treatment could improve mortality and morbidity associated 
with major CVD progression (Dormandy et al 2005). This 
review summarizes the key results from PROactive and 
puts them in context with other outcome trials in type 2 
diabetes.
Why should pioglitazone improve 
macrovascular outcomes?
Several lines of evidence suggest that pioglitazone has 
antiatherogenic properties and the potential to improve 
macrovascular outcomes in patients with type 2 diabetes. 
Firstly, pioglitazone produces long-term improvements 
in insulin sensitivity (Pavo et al 2003; Tan et al 2004a; 
Roden et al 2005) and insulin resistance is associated with 
an increased rate of atherosclerosis (Nigro et al 2006). 
Furthermore, pioglitazone improves multiple established 
modiﬁ  able risk factors for CVD, eg, atherogenic diabetic 
dyslipidemia (low HDL-cholesterol, raised triglycerides, 
and a preponderance of small, dense LDL particles) 
and blood pressure (Taskinen 2003; Buse et al 2004; 
Lawrence et al 2004; Perez et al 2004; Goldberg et al 2005; 
Derosa et al 2005a).
In line with its current role as a glucose-lowering therapy, 
pioglitazone produces long-term improvements in glycemic 
control, as evident in the sustained improvements in HbA1c 
and fasting plasma glucose seen in patients with type 2 
diabetes in clinical trials up to 2 years in duration (Hanefeld 
et al 2004; Schernthaner et al 2004; Tan et al 2004c; 
Charbonnel et al 2005a, b). However, it should be noted that 
it has not been ﬁ  rmly established that improving glycemia 
per se can signiﬁ  cantly improve macrovascular outcomes 
in type 2 diabetes, although data from the United Kingdom 
Prospective Diabetes Study (UKPDS) suggest a trend 
(UKPDS33 1998; Stratton et al 2000). In type 1 diabetes, 
on the other hand, intensive glucose-lowering therapy is 
associated with reductions in markers of inﬂ  ammation, ath-
erosclerosis and CVD, as well as a signiﬁ  cant reduction in 
macrovascular events (Nathan et al 2003, 2005; Schaumberg 
et al 2005; The DCCT Research Group 1993).
Pioglitazone also improves multiple non-traditional 
risk markers and emerging risk factors for CVD. Notably, 
pioglitazone signiﬁ  cantly reduces C-reactive protein (CRP) 
levels and improves the levels of a host of other cytokines, 
inflammatory mediators, and markers of endothelial 
dysfunction with a potential role in atherosclerosis (for 
example adiponectin, the matrix metalloproteinase, 
MMP-9, and plasminogen activator inhibitor-1 [PAI-1]) 
(Satoh et al 2003; Derosa et al 2005b; Miyazaki et al 2004; 
Pfutzner et al 2005). Pioglitazone has also been shown to 
reduce carotid intima media thickness, a surrogate marker 
for atherosclerosis, in a glucose-independent manner 
(Langenfeld et al 2005; Pfutzner et al 2005). Pioglitazone 
and other thiazolidinediones also reduce restenosis and 
neointimal tissue proliferation after coronary stent implanta-
tion in patients with or without type 2 diabetes (Takagi et al 
2000, 2003; Choi et al 2004; Marx et al 2005). Studies in 
the isolated rat heart model suggest another potential beneﬁ  t 
that may be relevant to improving outcomes – pioglitazone 
mimics ischemic preconditioning, which may protect the 
myocardium against subsequent prolonged episodes of lethal 
ischemia (Wynne et al 2005). 
The PROactive study was designed to examine whether 
the incidence of macrovascular events is reduced in patients 
given pioglitazone or placebo in combination with their 
usual medication for diabetes and CVD. The primary 
composite endpoint of the surrogate vascular endpoints of 
all-cause mortality, MI, acute coronary syndrome (ACS), 
coronary intervention, major leg amputation, bypass surgery, 
or leg revascularization was chosen so as to capture all 
CV events. 
PROactive study design
The PROactive study design is well documented else-
where (Charbonnel et al 2004; Dormandy et al 2005; 
www.proactive-results.com). Briefly, it was a prospec-
tive, multicenter, European (19 countries), randomized, 
double-blind outcome study in patients with type 2 
diabetes (35–75 years). All patients had a history of pre-
existing extensive macrovascular disease (MI, stroke, 
percutaneous coronary intervention or coronary artery 
bypass surgery ≥6 months before study entry, ACS ≥3 
months before study entry, or objective evidence of 
coronary artery disease or obstructive arterial disease in 
the leg) making the patient population at very high-risk 
for macrovascular disease. 
Patients were randomized to receive pioglitazone 
(titrated from 15 mg to 45 mg; n = 2605) or matched placebo 
(n = 2633) in addition to existing therapies. These included 
blood glucose-lowering drugs (with or without insulin), and Vascular Health and Risk Management 2007:3(4) 357
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Table 1 Concomitant glucose-lowering medication use during the study
     Pioglitazone        Placebo   
    Baseline  Final visit  Absolute    Baseline  Final visit  % Absolute 
    (% pts)  (% pts)  change  (% pts)  (% pts)  change 
        from baseline      from baseline
Any glucose-  95.8  91.6  −4.2% 96.0  95.5  −0.5%
lowering medication
Any  insulin  33.2 35.9  +2.7%  34.0 46.4  +12.4%
Any metformin  61.2  58.1  −3.1% 61.8  63.6  +1.8%
Sulfonylurea 62.3  53.3  −9.0% 61.8  52.2  −9.6%
Abbreviations: pts, patients.
lipid-lowering, antihypertensive, and antiplatelet therapies 
(Tables 1 and 2) – many patients were already receiving 
contemporary multifactorial therapy. The primary endpoint 
was the time from randomization to the ﬁ  rst incidence of 
all-cause mortality, non-fatal MI (including silent MI), 
stroke, major leg amputation, ACS, cardiac intervention 
(bypass graft or percutaneous coronary intervention), or 
leg revascularization. This very challenging composite 
endpoint therefore included procedural endpoints and 
was designed to demonstrate beneﬁ  t in multiple vascular 
beds – cardiac, cerebral, and peripheral. The main secondary 
endpoint was time to ﬁ  rst incidence of all-cause mortality, 
non-fatal MI, or stroke – this represented the most clinically 
important and objectively conﬁ  rmed events and is identical 
or similar to primary composite endpoints used in many 
other major CV outcome studies. Although not included 
in the original study design (Charbonnel et al 2004), this 
main secondary endpoint was prespeciﬁ  ed in the statistical 
analysis plan prior to unblinding (Dormandy et al 2006; 
www.proactive-results.com). 
Throughout the study, investigators were encouraged 
to strive for a target HbA1c <6.5% and to increase 
lipid-altering, antiplatelet, and antihypertensive therapy to 
an optimum in line with IDF Europe guidelines (European 
Diabetes Policy Group 1999). The duration of the study 
was event-driven – however, due to faster than anticipated 
enrolment and a higher event rate than predicted, the study 
was amended to include a minimum duration of follow-up 
of 30 months.
Main outcome results in PROactive
After a mean follow-up of 34.5 months, patients in the 
pioglitazone group experienced 803 events, of which 514 
were ﬁ  rst events, whereas those on placebo had 900 events, 
of which 572 were ﬁ  rst events. For the primary composite 
endpoint, pioglitazone reduced the relative risk for an event 
Table 2 Concomitant cardiovascular medication use during the study
   Pioglitazone        Placebo   
  Baseline  Final visit  Absolute    Baseline  Final visit  % Absolute 
  (% pts)  (% pts)  change  (% pts)  (% pts)  change 
      from baseline      from baseline
Any cardiovascular medication  95.1  96.2  1.1%  94.8  96.5  1.7%
 ACE  inhibitors  62.6  64.8  2.2%  63.0  66.7  3.7%
 β -blockers 54.6  57.9  3.3%  54.5  60.6  6.1%
  Angiotensin II antagonists  6.5  9.6  3.1%  7.0  10.9  3.9%
  Calcium channel blockers  34.2  35.4  1.2%  36.6  39.5  2.9%
 Nitrates  39.1  35.8  –3.3%  39.7  34.8  –4.9%
 Thiazide  diuretics  15.4  18.5  +3.1%  16.3  20.2  +3.9%
 Loop  diuretics  14.3  22.0  +7.7%  14.4  19.8  +5.4%
 Cardiac  glycosides  5.0  4.4  –0.6%  4.8  3.6  –1.2%
Antiplatelet medication  85.3  88.2  +2.9%  82.6  87.7  +5.1%
 Aspirin  74.5  76.2  +1.7%  71.7  73.9  +2.2%
Lipid-altering medication  50.7  61.8  11.1%  52.6  62.7  10.1%
 Statins    42.5  55.0  +12.5%  43.2  55.5  +12.3%
 Fibrates  10.1  8.6  –1.5%  11.2  10.1  –1.1%
Abbreviations: pts, patients.Vascular Health and Risk Management 2007:3(4) 358
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by 10% compared with placebo, but this difference did not 
achieve statistical signiﬁ  cance (Figure 1A). Nevertheless, 
there was a consistent reduction in most of the individual 
components of the primary endpoint – the risk of mortality, 
non-fatal MI, silent MI, stroke, major leg amputation, 
and ACS was lower with pioglitazone relative to placebo 
(Table 3). For the main secondary endpoint, pioglitazone was 
associated with a 16% relative risk reduction (Figure 1B). 
Figure 1  Main outcome results in PROactive. A. Primary composite endpoint (all-cause mortality, non-fatal MI (including silent MI), stroke, major leg amputation, acute 
coronary syndrome, cardiac intervention, or leg revascularization); B. Main secondary composite endpoint (all-cause mortality, non-fatal MI, or stroke). Both ﬁ  gures repro-
duced with permission from Dormandy JA, Charbonnel B, Eckland DJ, et al. 2005. PROactive investigators. Secondary prevention of macrovascular events in patients with 
type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 366:1279–89. Copyright © 
2005 Elsevier.
B
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Adding pioglitazone to the medication of 1000 patients would, 
therefore, avoid 21 ﬁ  rst MIs, strokes, or deaths over 3 years. 
In other words, the number needed to treat (NNT) would be 
48 patients for 3 years to avoid one ﬁ  rst major CV event.
The difference between the two main composite 
endpoints was explained mainly by an unexpected increase 
in the number of peripheral vascular procedures performed 
in the pioglitazone group. There was also no decrease in the 
number of coronary revascularization procedures included 
in the primary endpoint; however, there was a decrease in 
the number of coronary revascularization procedures in the 
pioglitazone group overall during the study (including those 
that were not the ﬁ  rst event) (Table 3). 
Twenty-ﬁ  ve baseline variables were prespeciﬁ  ed for 
subgroup analysis. Interaction tests within these subgroups 
did not reveal evidence of heterogeneity. Multivariate 
analysis of the association of entry characteristics to the 
main secondary endpoint showed associations with several 
factors, such as statin use, insulin use, smoking, and previous 
MI. Nevertheless pioglitazone was associated with a 16% 
reduction in relative risk even after adjustment for these 
factors.
Composite endpoints of cardiovascular events, referred 
to as major adverse cardiovascular events (MACE), are 
standard measures for comparing treatments in large cardio-
vascular outcome studies. In addition to the main secondary 
endpoint, analyses of other prespeciﬁ  ed and post-hoc MACE 
endpoints have been presented recently for the overall patient 
population (Wilcox and Kupfer 2006). Pioglitazone treat-
ment resulted in signiﬁ  cant relative risk reductions in the 
prespeciﬁ  ed endpoint of risk of fatal/non-fatal MI (excluding 
silent MI) (HR = 0.77, 95% CI [0.60,1.00]; p = 0.046), and 
prespeciﬁ  ed endpoint of the composite of CV death, non-fatal 
MI (excluding silent MI), or non-fatal stroke (HR = 0.82, 
95% CI [0.70, 0.97]; p = 0.02). A post-hoc analysis also 
showed a signiﬁ  cant relative risk reduction for the composite 
of all-cause mortality, non-fatal MI (excluding silent MI), 
non-fatal stroke, or ACS (HR = 0.83, 95% CI [0.72, 0.96]; 
p = 0.010).
Metabolic and laboratory results
Laboratory data showed signiﬁ  cant improvements in HbA1c 
(–0.5%), triglycerides (–13.2%), HDL-cholesterol (+8.9%) 
and LDL-/HDL-cholesterol ratio (–5.3%) with pioglitazone 
relative to placebo (Table 4). The improvement in glycemic 
control occurred despite a 50% reduction in rate of progres-
sion to permanent insulin use (deﬁ  ned as daily insulin use for 
a period of ≥90 days, or ongoing use at death/ﬁ  nal visit) in the 
pioglitazone group compared with placebo – 183 patients on 
pioglitazone progressed to permanent insulin use during the 
study compared with 362 on placebo (Massi-Benedetti et al 
2006). The decreased need for insulin in the pioglitazone group 
was irrespective of baseline treatment. Furthermore, among 
patients receiving insulin at baseline, insulin doses progres-
sively decreased in the pioglitazone group during the study, 
but progressively increased with placebo and were signiﬁ  cantly 
different by study end (Scheen and Charbonnel 2006). There 
were no differences in changes in the use of other medications 
during the study, apart from a slight decrease in metformin 
use in the pioglitazone group compared with placebo (Table 
1). Signiﬁ  cant improvements in HbA1c of similar magnitude 
to the overall pioglitazone group were seen in patients who 
were on insulin at baseline (Scheen and Charbonnel 2006) or 
on dual oral agent therapy with metformin plus sulfonylureas 
at baseline (when pioglitazone was added as a third agent) 
(Charbonnel and Scheen 2006). 
Systolic blood pressure was signiﬁ  cantly improved in the 
pioglitazone group compared with placebo (between-group 
Table 3 Effects of pioglitazone and placebo on individual components of the composite endpoints and total events during the study
Endpoint   Primary composite     Secondary composite     Total events 
 Pioglitazone  Placebo  Pioglitazone Placebo  Pioglitazone Placebo
Any event  514  572  301  358  803  900
Death 110  122  129  142  177  186
Non-fatal MI (excl silent MI)  85  95  90  116  108  132
Silent MI  20  23  —  —  23  25
Stroke 76  96  82  100  92  119
Major leg amputation  9  15  —  —  28  28
ACS 42  63  —  —  65  78
Coronary revascularization  101  101  —  —  195  240
Leg revascularization  71  57  —  —  115  92
Abbreviations: ACS, acute coronary syndrome; MI, myocardial infarction. Vascular Health and Risk Management 2007:3(4) 360
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difference of –3 mmHg), with only a slight increase in the use 
of antihypertensive agents. Analyses of laboratory assessments 
for liver function (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], and alkaline phosphatase [AP]) have 
also been presented recently (Heine et al 2006). The results 
showed a general shift toward normalization of ALT and 
AST values in the pioglitazone group from baseline to ﬁ  nal 
visit compared with no change or an increase in the placebo 
group (p < 0.001 for difference between groups at ﬁ  nal visit). 
Changes in ALT with pioglitazone may reﬂ  ect a reduction in 
liver fat due to improvement in hepatic insulin sensitivity.
Subgroup analyses
The ﬁ  rst prespeciﬁ  ed subgroup analysis involved the cohort of 
2445 patients with a previous MI ≥ 6 months prior to random-
ization (Erdmann et al 2007). Prespeciﬁ  ed endpoints were time 
to fatal or non-fatal MI (excluding silent MI), time to CV death 
or non-fatal MI, and time to CV death, non-fatal MI, or stroke. 
Time to fatal or non-fatal MI was signiﬁ  cantly reduced by 28% 
in the pioglitazone group relative to placebo (Figure 2A). Risk of 
CV death or non-fatal MI, and risk of CV death, non-fatal MI, or 
stroke were both reduced by 15% with pioglitazone relative to 
placebo, but neither reached statistical signiﬁ  cance. In addition, 
several post-hoc exploratory endpoints were analyzed for this 
subgroup. Risk of experiencing an event in a cardiac composite 
endpoint of cardiac death, non-fatal MI (excluding silent MI), 
ACS, and coronary revascularization was signiﬁ  cantly reduced 
by 19% in the pioglitazone group relative to the placebo group 
(Figure 2B). There was no signiﬁ  cant reduction in relative risk 
when silent MI was included in this composite endpoint or in 
any of its individual components, except for risk of an ACS, 
which was signiﬁ  cantly reduced by 37% with pioglitazone 
relative to placebo.
Another prespeciﬁ  ed subgroup analysis compared out-
comes in patients with (n = 984) or without (n = 4254) prior 
stroke (Wilcox et al 2007). Risk of a recurrent stroke was 
signiﬁ  cantly reduced by 47% with pioglitazone relative to 
placebo in patients with prior stroke (HR = 0.53; 95% CI 
[0.34, 0.85]; p = 0.0085), whereas no signiﬁ  cant difference 
in the relative risk of stroke was seen in patients without a 
prior stroke. For the composite of CV death, MI, or stroke 
there was also a signiﬁ  cant relative risk reduction with 
pioglitazone in patients with prior stroke (HR = 0.72; 95% 
CI [0.52, 1.00]; p = 0.0467). 
Were there any potential safety 
or tolerability issues in PROactive?
The overall frequency of serious adverse events was slightly 
lower in the pioglitazone group, even after events contributing 
to the primary composite endpoint were excluded. The 
incidence of adverse events reported as “heart failure” has 
received considerable attention in the critical appraisal of 
the results from PROactive (Yki-Järvinen 2005). Regarding 
serious heart failure as reported by the investigators, 5.7% 
of pioglitazone-treated patients were reported with heart 
failure leading to hospitalization compared with 4.1% of 
placebo-treated patients; however, rates of mortality due to 
heart failure were similar between the two groups (0.96% 
[n = 25 out of 2605] vs 0.84% [n = 22 out of 2633] for 
pioglitazone and placebo, respectively). Despite more reports 
of heart failure in the pioglitazone group, overall CV outcomes 
were improved and the number of CV endpoints after serious 
heart failure was also similar between treatment groups 
(Erdmann et al 2006). Furthermore, most investigator-reported 
cases of serious heart failure resolved and were not treatment-
limiting. Only 34 of the 113 patients in the pioglitazone group 
and 17 out of 89 patients in the placebo group who were on 
therapy at the time of diagnosis of heart failure discontinued 
study drug. Therefore, only a little more than 1% of patients in 
the pioglitazone group discontinued study drug for this reason. 
Edema in the absence of heart failure was reported in 21.6% 
of patients treated with pioglitazone compared with 13.0% on 
placebo. An independent review of the heart failure cases was 
conducted by assessing the strength of evidence of the patients 
having a history of heart failure before entering the study 
and also for each reported case of serious heart failure. This 
conﬁ  rmed the accuracy of the original investigator diagnoses 
of greater rates of non-serious and serious heart failure in the 
Table 4 Change in metabolic parameters from baseline to ﬁ  nal visit
 Pioglitazone  Placebo  p-value
HbA1c (% absolute change)  –0.8 [–1.6, –0.1]  –0.3 [–1.1, 0.4]  <0.001
Triglycerides (% change)  –11.4 [–34.4, 18.3]  1.8 [–23.7, 33.9]  <0.001
LDL-cholesterol (% change)  7.2 [–11.2, 27.6]  4.9 [–13.9, 23.8]    0.0034
HDL-cholesterol (% change)  19.0 [6.6, 33.3]  10.1 [–1.7, 21.4]  <0.001
LDL/HDL (% change)  –9.5 [–27.3, 10.1]  –4.2 [–21.7, 15.8]  <0.001
Data are median [interquartile range].Vascular Health and Risk Management 2007:3(4) 361
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pioglitazone arm, but comparable rates of mortality due to 
heart failure (Rydén et al 2007).
It should be emphasized that there is no evidence available 
in the literature to suggest that pioglitazone or other 
thiazolidinediones have any adverse effect on cardiac function. 
In clinical practice, initiation of pioglitazone therapy (alone 
or as an addition to pre-existing therapies, such as other oral 
agents and/or insulin) does not appear to be associated with 
increased hospitalization due to heart failure over a 10-month 
follow-up compared with initiation of sulfonylureas as a 
standard reference diabetes therapy (Karter et al 2005). Initia-
tion of insulin, on the other hand, is associated with a signiﬁ  cant 
increase. Furthermore, 52 weeks of therapy with rosiglitazone 
was shown to have no adverse effect on cardiac structure or 
function (left ventricular [LV] mass index, ejection fraction, 
and left ventricular end-diastolic volume) (St John Sutton 
Figure 2  Outcomes in the subgroup of patients with a previous myocardial infarction (MI).  A. Prespeciﬁ  ed endpoint of fatal/non-fatal MI (excluding silent MI); B. Ex-
ploratory composite cardiac endpoint (cardiac death, non-fatal MI, coronary revascularization, or acute coronary syndrome). Figure 2A reproduced with permission from 
Erdmann E, Dormandy JA, Charbonnel B, et al; on behalf of the PROactive investigators 2007. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients 
with type 2 diabetes and previous myocardial infarction – Results from PROactive (PROactive 05). J Am Coll Cardiol, 49:1772–80. Copyright © 2007 Elsevier. 
A
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et al 2002). In fact, pioglitazone has been shown actually to 
improve LV diastolic function without LV mass regression 
in hypertensive patients in proportion to the amelioration of 
insulin resistance (Horio et al 2005). Animal models support 
these observations. Pioglitazone improved LV remodeling and 
function in mice with post-MI heart failure, an effect that was 
associated with an attenuated LV expression of inﬂ  ammatory 
cytokines (Shiomi et al 2002). Such studies have led to the 
suggestion that thiazolidinediones may, in fact, have thera-
peutic potential in patients with advanced heart failure, rather 
than being a cause for concern (Nikolaidis and Levine, 2004). 
However, it should be noted that edema is more frequent in 
patients treated with pioglitazone plus insulin – ﬂ  uid retention 
is a dose-dependent side-effect of both drugs. 
In PROactive, average weight gain from baseline with 
pioglitazone was 3.6 kg (compared with –0.6 kg for placebo). 
However, weight gain led to permanent discontinuation in 
only 0.8% of patients compared with 0.2% on placebo. Weight 
gain with thiazolidinediones is a consistent ﬁ  nding and may 
reﬂ  ect a combination of both fat increase and ﬂ  uid retention 
(Hollenberg 2003). Any possible detrimental effect of increased 
body fat is offset by potentially beneﬁ  cial qualitative effects 
– thiazolidinediones shift fat distribution away from the more 
metabolically active visceral depots to less active subcutane-
ous depots (an effect associated with improvements in hepatic 
and peripheral insulin sensitivity) (Miyazaki et al 2002). The 
overall incidence of cancer in PROactive was equivalent in the 
pioglitazone and placebo groups (3.7% vs 3.8%, respectively). 
Although there was a slight increase in the number of bladder 
tumors (n = 14 vs 6) and a slight decrease in breast tumors 
(n = 3 vs 11) reported in the pioglitazone group, an external 
independent review of blinded data concluded that any causal 
link was unlikely. 
How does PROactive compare 
with other outcome studies 
in type 2 diabetes?
Several intervention trials using antihypertensive agents, 
lipid-modifying drugs (principally statins), glucose-lowering 
agents, or multifactorial intervention strategies have looked 
at macrovascular outcomes in patients with type 2 diabe-
tes. However, much of the data pertaining to patients with 
diabetes are post-hoc or, in some instances, predeﬁ  ned sub-
group analyses from larger cohorts (Table 5). Comparison 
between the results of PROactive and previous outcome 
studies is complicated by differences in predeﬁ  ned endpoints, 
study population, study duration, concomitant medication 
use, and a range of other methodological issues.
To date, no prospective studies have been able to 
establish conclusively whether improving hyperglycemia 
per se in patients with type 2 diabetes can improve 
macrovascular outcomes. However, the UKPDS showed a 
clear trend towards a reduction in primary macrovascular 
events (based on a secondary endpoint of fatal/non-fatal 
MI) in patients whose hyperglycemia was more intensively 
managed with pharmacologic therapy (using sulfonylureas 
or insulin) compared with conventional management us-
ing lifestyle interventions (UKPDS33 1998). Subsequent 
observational analyses showed that each 1% reduction in 
HbA1c was associated with a 14% relative reduction in 
risk for MI (Stratton et al 2000). However, in a substudy 
of overweight patients, tight glycemic control with met-
formin signiﬁ  cantly reduced the two secondary endpoints 
of MI and any macrovascular disease (UKPDS34 1998), 
suggesting an effect independent of glucose control in 
this patient group. Secondary endpoint measures from a 
prospective placebo-controlled diabetes prevention study 
suggested that acarbose (an α-glucosidase inhibitor that 
reduces postprandial hyperglycemia) may reduce the 
development of major CV events in people with impaired 
glucose tolerance, although the total number of events 
was low (Chiasson et al 2003). In type 1 diabetes, the 
beneﬁ  ts of reducing hyperglycemia appears to be less am-
biguous, and the recent 17-year follow-up of the Diabetes 
Control and Complications Trial (DCCT) showed that 
intensive treatment caused a signiﬁ  cant 57% reduction in 
macrovascular events among intensively-treated patients 
that was explained principally by a sustained decrease in 
HbA1c (HbA1c decreases at Year 11 were the same in both 
the intensive and conventional treatment groups; Nathan 
et al 2005). 
Statin use in PROactive was not completely optimal 
for such a high-risk patient group (approximately 43% at 
baseline increasing to 55% at study end in both groups). 
Nevertheless, it reﬂ  ects or possibly even exceeds the levels 
seen in contemporary practice among patients with diabetes 
with or without established coronary heart disease (CHD) 
and other high-risk patients (Brown et al 2004; Ko et al 2004; 
Emberson et al 2005; Bhatt et al 2006). 
The 5-year Cholesterol And Recurrent Events (CARE) 
trial looked at secondary prevention in patients with 
a previous MI and had major coronary events (CHD death, 
non-fatal MI, or coronary revascularization) as a primary 
endpoint (Goldberg et al 1998). This provides similar 
criteria for comparison with the previous MI subgroup 
in PROactive using the post-hoc exploratory composite Vascular Health and Risk Management 2007:3(4) 363
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Table 5 Placebo-controlled outcome trials
Trial Population  n  Study  Intervention  Positives  Negatives
       duration
PROactive Secondary  5238  34.5  Pioglitazone  •  Signiﬁ  cant 16% relative   •  Primary endpoint did not
(Dormandy  prevention in    months      risk reduction in the    reach signiﬁ  cance
et al 2005)  type 2 diabetes          endpoint of all-cause  •  Study duration relatively
  and established          mortality, stroke, and MI    short (3 years)
  macrovascular        •  Prevention of recurrent  •  Higher rates of serious
  disease          stroke and MI    heart failure with
            •  Effects were observed on    pioglitazone 
              top of guideline-directed    (but fatal heart failure
              background CV and    rates were similar)
             diabetes  medication   
UGDP  Primary     823  5.5 years  Tolbutamine  •  First large-scale  •  Failed to show any beneﬁ  t
(Meinert   prevention in      Insulin    intervention study    of glucose control on
et al 1970)  patients with            vascular events in type 2
  type 2 diabetes            diabetes
             •  Inconclusive  ﬁ  ndings in the
                insulin groups in terms of 
                delaying or preventing CV
               complications
              •  Increased relative risk of
                cardiac events with
               tolbutamine
             •  No  signiﬁ  cant difference
                in incidence of overall
                mortality in all of the groups
              •  Small patient number and
                poor patient follow-up
UKPDS  Primary   342  10.7 years  Metformin  •  Metformin signiﬁ  cantly  • The number of patients
(UKPDS 34  prevention in  (out of        reduced MI (by 39%)    allocated to metformin 
1998)  newly  5102)        and any diabetes-related    was less than 10% 
  diagnosed           endpoint (by 32%)     of the total patient
  drug-naïve          relative to lifestyle     population in the UKPDS 
  with type          management    and effects were only
  2 diabetes            assessed in a population of 
               obese  people
              • The reduction in micro-
                vascular events was not
               statistically  signiﬁ  cant 
                (unlike the results seen in
                the main study)
CARDS   Primary   2838  3.9 years  Atorvastatin  •   Trial terminated 2 years  •  Most participants had long-
(Colhoun   prevention in           earlier as the prespeciﬁ  ed    standing diabetes with
et al 2004)  patients with           early stopping rule     multiple additional risk 
  type 2 diabetes           for efﬁ  cacy had been met    factors that were
  and CV risk        •  37% decrease in CV events    substantially undertreated
              and 48% decrease in stroke  
              with atorvastatin relative 
             to  placebo
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FIELD  Primary and  9795  5 years  Fenoﬁ   brate  • Largest  intervention  • Primary  endpoint
(Keech et al  secondary          study in diabetes to date    (non-fatal MI or CHD death
2005) prevention  in       •  Signiﬁ  cant relative    did not reach signiﬁ  cance
  patients with          reduction in  • There was a 19% 
  type 2 diabetes          non-fatal MI (by 24%)    relative increase in
  and varying levels        •  Signiﬁ  cant 11% relative    CHD mortality with
  of dyslipidemia          risk reduction in    fenoﬁ  brate therapy
            main secondary outcome  •  Statin use during the study
            (composite of MI, stroke,     was a confounding factor
            CVD death, and coronary  •  Fenoﬁ  brate appeared
            and carotid     to confer beneﬁ  t only in
            revascularization)    the primary prevention
             of CVD and increased
              relative risk in patients
              with prior CVD
           • Fenoﬁ  brate only 
             reduced CVD events
             in patients <65 years
HOPE  Secondary  3577  4.5 years  Ramipril  • Signiﬁ  cant 25% relative  • The analysis in patients
(HOPE study  prevention  (out of       risk reduction with   with diabetes, but without
investigators  in high-CV  9541)       ramipril in the primary   overt CVD
2000)  risk patients          composite endpoint of    did not reach
  (subgroup          CV death, MI or stroke    statistical signiﬁ  cance
 analysis        •  Signiﬁ  cant relative risk  • There was a high
  in patients          reduction with ramipril    discontinuation rate
  with type 2          in MI, stroke, total    due to side effects
 diabetes)          mortality and CV death 
HOT  Secondary  1501  3.8 years  Aspirin  • There was a 66%  •   No effect on
(Hansson  prevention  (out of    (+ others)    relative risk reduction    stroke prevention
et al 1998)   (subgroup  18,790)        in mortality and a 51%  •   Non-fatal major
  analysis in          relative risk reduction    bleeds were twice
  patients with          in major CV events    as common in the
  type 2 diabetes)          with aspirin    aspirin group
CARE  Secondary  586   5 years  Pravastatin  •  22% relative risk  •   At the 3-year point,
(Goldberg  prevention in  (out of        reduction in CV events    pravastatin produced 
et al 1998)  patients with  4159)          no beneﬁ  t 
 previous  MI           
 (diabetes           
 subgroup)           
PROSPER   Secondary  623  3.2 years  Pravastatin    •   Non-signiﬁ  cant 27%
(Shepherd  prevention in  (out          increase in the relative
et al 2002)  elderly patients  of 5804)          risk of CV death, stroke,
  with a history            or MI with pravastatin
  of/risk for CVD          •   Number of patients
  (diabetes            with diabetes too small
  subgroup)            to permit accurate
               interpretation of any
             treatment  effect
           •   Patient population
             ≥70 years
Table 5 (Continued)
Trial Population  n  Study  Intervention  Positives  Negatives
     duration
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endpoint of cardiac death, non-fatal MI, ACS, or coronary 
revascularization (Figure 3A). Patients in PROactive had 
a higher event rate than patients in CARE. At the 3-year 
point, pravastatin therapy in CARE produced no beneﬁ  t in 
these patients, whereas in PROactive there was a signiﬁ  cant 
19% relative risk reduction with pioglitazone. An analysis 
of the 5963 patients with diabetes in the Heart Protection 
Study (HPS), around 50% of whom had a previous history 
of CVD, showed that simvastatin reduced the relative risk 
of major vascular events by approximately 17% after 3 
years (Figure 3B). In the pravastatin in elderly individuals 
at risk of vascular disease (PROSPER) study (Shepherd 
et al 2002), which included individuals with a history of 
(or risk of) vascular disease, the length of follow-up (3.2 
years) was very similar to that in PROactive. Among the 
623 patients with diabetes, those treated with pravastatin 
appeared to have a non-signiﬁ  cant 27% increase in the risk 
of an event (CV death, stroke, or MI), although there was 
a signiﬁ  cant risk reduction in the population overall, and 
the authors considered the number of patients with diabetes 
too small to permit accurate interpretation of any treatment 
effect. The recent FIELD study was the largest intervention 
study to date in patients with type 2 diabetes (Keech et al 
2005). The rather heterogeneous study population included 
patients with varying levels of dyslipidemia, only 22% of 
whom had a prior history of CVD. After a median 5 years 
of follow-up, the primary outcome (non-fatal MI or CHD 
death), was reduced by 11% with fenoﬁ  brate compared with 
placebo, but this did not achieve statistical signiﬁ  cance. 
A signiﬁ  cant 24% decrease in non-fatal MI was offset by a 
non-signiﬁ  cant 19% increase in CHD mortality. However, 
patients were statin-naïve at baseline and signiﬁ  cantly more 
patients in the placebo group commenced statin therapy dur-
ing the study so this may have been a confounding factor. 
Interestingly, fenoﬁ  brate seemed to reduce events only in 
those patients with no previous CVD (19% decrease). In 
patients with prior CVD, there was a slight (2%) increase 
in relative risk. For the main secondary outcome (com-
posite of MI, stroke, CVD death, and coronary and carotid 
revascularization), there was a statistically signiﬁ  cant 11% 
reduction in risk overall.
The vast majority of patients in PROactive were receiving 
antihypertensive and antiplatelet therapy with comparable 
proportions in the two treatment groups, and all patients 
were treated to an HbA1c goal of <6.5% (96% were using 
glucose-lowering agents) (Tables 1 and 2). The signiﬁ  cant 
impact of antihypertensive therapy on macrovascular 
outcomes in type 2 diabetes has been demonstrated in several 
large-scale trials, including the UKPDS (primary prevention), 
the Heart Outcomes Prevention Evaluation (HOPE) study 
(mixed secondary/primary prevention) and GISSI-3 (second-
ary prevention) (Zuanetti et al 1997; UKPDS38 1998; HOPE 
2000). An analysis from the HOPE study, which included 
3577 patients with diabetes (approximately two-thirds with a 
HPS  Primary and  2912  5 years  Simvastatin  •   33% relative risk  •  10% had type 1 diabetes
(HPS  secondary  (out of       reduction in CV events  
Collaborative  prevention in  20,536)        
Group 2003)  patients with           
 CVD  (diabetes         
 subgroup)
4S  Secondary  483 (out  5.4 years  Simvastatin  •   42% relative risk  • The event rate was very
(Pyörälä  prevention in  of 4398)        reduction in CHD events    high (45%) in the 
et al 1997)  patients with            placebo group
 CHD  (diabetes             
 subgroup) 
LIPID
(LIPID Study   Secondary      782  6.1 years  Pravastatin    •  Non-signiﬁ  cant 16%
Group 1998)  prevention in  (out          relative risk reduction 
  patients with  of 9014)          in CV events 
  known heart            with pravastatin 
 disease     
 (diabetes   
 subgroup)   
Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease.
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Figure 3 A. Major cardiac outcomes in the PROactive subgroup with previous myocardial infarction (MI) compared with outcomes in the CARE study.  All patients in 
CARE had diabetes and a previous MI (from data of Goldberg 1998); B. Major vascular outcomes (major coronary events, stroke, and revascularization in patients with 
diabetes) in the HPS study (from data of Heart Protection Study Collaborative Group 2003). Figure 3A reproduced with permission from Goldberg RB, Mellies MJ, Sacks 
FM, et al. 1998 for the Care Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with 
average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation, 98:2513–9. Copyright © 1998 Lippincott Williams and Wilkins. 
Figure 3B reproduced with permission from Heart Protection Study Collaborative Group. 2003. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin 
in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 361:2005–16. Copyright © 2003 Elsevier. 
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history of CVD and one-third with ≥1 CV risk factor), com-
pared treatment with the ACE inhibitor ramipril with placebo. 
By 3 years, a relative risk reduction of approximately 25% 
was seen in the ramipril group for the primary composite 
endpoint of CV death, MI, or stroke (HOPE 2000). 
An analogy has been made between PROactive and the 
Steno-2 study, which had an almost identical primary end-
point (Gaede et al 2006). Steno-2 showed a 20% absolute risk 
reduction and a 53% relative risk reduction after intensiﬁ  ed 
multifactorial intervention compared with standard multifacto-
rial intervention (Gaede et al 2003, 2006). However, this was 
a comparatively small study (n = 180), with an 8-year follow-
up in patients with microalbuminuria, the majority of whom 
had no pre-existing major CVD. Furthermore, signiﬁ  cantly 
fewer patients in the control group received statins (n = 57 
vs 14), antihypertensives, or antiplatelet therapy, whereas in 
PROactive, patients in both groups were receiving compa-
rable multifactorial interventions at baseline and at study end 
(statins, ﬁ  brates, antihypertensives, and antiplatelet therapy). 
Any effect of pioglitazone should therefore be considered as 
additional to these interventions. Use of antihypertensives and 
antiplatelet therapy was similar between PROactive and the 
intensive group in Steno-2 (although statin use was lower in 
PROactive (43% increasing to 55% at study end)). 
Conclusion
What are the implications of PROactive?
PROactive has shown that pioglitazone can signiﬁ  cantly 
reduce the risk of secondary macrovascular events in a very 
high-risk patient population with established macrovascu-
lar disease, the majority of whom were receiving optimal 
treatment of established CV risk factors. As this patient 
population carries an excess risk, even with attention to 
established risk factors, pioglitazone may therefore provide 
an additional option to reduce residual events further as part 
of a multifactorial intervention strategy. 
What questions remain unanswered 
after PROactive?
Several outcomes studies with thiazolidinediones are 
currently underway including IRIS (Insulin Resistance 
Intervention After Stroke) (http://iristrial.org) and RECORD 
(Rosiglitazone Evaluated of Cardiac Outcomes and Regu-
lation of Glycemia in Diabetes) that aim to evaluate the 
long-term impact of these effects on CV outcomes and on 
long-term glycemic control in people with type 2 diabetes 
(Home et al 2005) and BARI 2D (Bypass Angioplasty 
Revascularization Investigation in Type 2 Diabetics; Sobel 
et al 2003). The results of the Diabetes Reduction Approaches 
with ramipril and rosiglitazone Medications (DREAM) study 
were presented at the 2006 European Association for the 
Study of Diabetes (EASD) meeting and have been published 
in The Lancet (DREAM Trial Investigators 2006). In the 
enrolled population of 5,269 people with impaired glucose 
tolerance and/or impaired fasting glucose, rosiglitazone did 
not reduce all-cause mortality within 3 years of treatment 
(30 patients [1.1%] in the rosiglitazone group and 33 [1.3%] 
in the placebo group died). There was a trend for a higher 
number of events from the CV composite in the rosiglitazone 
group (75 [2.9%] events vs 55 [2.1%] in the placebo group; 
HR 1.37; 95% CI 0.97, 1.94; p = 0.08) that was driven by a 
higher rate of heart failure in the rosiglitazone group (0.5%; 
n = 14) than in the placebo group (0.1%, n = 2; HR 7.03; 
95% CI 1.60, 30.9; p = 0.01). There were no cases of fatal 
heart failure during the study. It should be noted, however, 
that DREAM was a trial designed for primary prevention 
of manifest type 2 diabetes in patients with the metabolic 
syndrome and as such targeted towards glycemia outcomes 
and not towards prevention of CV risk.
PROactive has presented a range of questions that will 
hopefully be clariﬁ  ed with further analyses and through the 
results of these ongoing outcomes studies. For instance, it 
is unclear which effects of pioglitazone underlie its antiath-
erogenic effects – glucose-lowering, lipid regulation (effects 
on HDL-cholesterol, triglycerides, or LDL particle size), 
other pleiotropic factors (effects on inﬂ  ammatory mediators, 
such as CRP), or a combination of factors. It is also unclear 
whether these results can be extrapolated to thiazolidinedio-
nes in general, considering some of their mechanistic distinc-
tions, such as differing effects on lipid proﬁ  les (Goldberg 
et al 2005). Furthermore, it is not known whether a longer 
duration study would have resulted in a signiﬁ  cant impact 
on the primary endpoint, or how effective pioglitazone 
would be in these patients if attention to antiplatelet therapy, 
blood pressure therapy, and, in particular, lipid-modifying 
therapy had been fully optimized. PROactive was a second-
ary prevention study, and we do not know if these results 
can be extrapolated to the wider population of patients with 
type 2 diabetes (such as in primary prevention), or indeed to 
those with prediabetes or high-risk patients without diabetes. 
Finally, the real impact (if any) of pioglitazone on heart 
failure is unclear at present.
References
Bhatt DL, Steg PG, Ohman EM, et al. 2006. REACH Registry Investigators. 
International prevalence, recognition, and treatment of cardiovascular 
risk factors in outpatients with atherothrombosis. JAMA, 295:180–9.Vascular Health and Risk Management 2007:3(4) 368
Erdmann et al
Brown LC, Johnson JA, Majumdar SR, et al. 2004. Evidence of suboptimal 
management of cardiovascular risk in patients with type 2 diabetes 
mellitus and symptomatic atherosclerosis. CMAJ, 171:1189–92.
Buse JB, Tan MH, Prince MJ, et al. 2004. The effects of oral anti-
hyperglycaemic medications on serum lipid proﬁ  les in patients with 
type 2 diabetes. Diabetes Obes Metab, 6:133–56.
Charbonnel B, Dormandy J, Erdmann E, et al. 2004. PROactive Study 
Group. The prospective pioglitazone clinical trial in macrovascular 
events (PROactive): can pioglitazone reduce cardiovascular events in 
diabetes? Study design and baseline characteristics of 5238 patients. 
Diabetes Care, 27:1647–53.
Charbonnel B, Scheen A. 2006. Pioglitazone in triple oral therapy: 
long-term glycaemic results from PROactive [abstract]. Diabetes, 
55(Suppl 1):A106.
Charbonnel BH, Matthews DR, Schernthaner G, et al. 2005a. QUARTET 
Study Group. A long-term comparison of pioglitazone and gliclazide 
in patients with Type 2 diabetes mellitus: a randomized, double-blind, 
parallel-group comparison trial. Diabet Med, 22:399–405.
Charbonnel B, Schernthaner G, Brunetti P, et al. 2005b. Long-term efﬁ  cacy 
and tolerability of add-on pioglitazone therapy to failing monotherapy 
compared with addition of gliclazide or metformin in patients with type 
2 diabetes. Diabetologia, 48:1093–104.
Chiasson JL, Josse RG, Gomis R, et al. 2003. STOP-NIDDM Trial Research 
Group. Acarbose treatment and the risk of cardiovascular disease and 
hypertension in patients with impaired glucose tolerance: the STOP-
NIDDM trial. JAMA, 290:486–94.
Choi D, Kim SK, Choi SH, et al. 2004. Preventative effects of rosiglitazone 
on restenosis after coronary stent implantation in patients with type 2 
diabetes. Diabetes Care, 27:2654–60.
Colhoun HM, Betteridge DJ, Durrington PN, et al. 2004. CARDS investigators. 
Primary prevention of cardiovascular disease with atorvastatin in type 2 
diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): 
multicentre randomized placebo-controlled trial. Lancet, 364:685–96.
The Diabetes Control and Complications Trial Research Group. 1993. 
The effect of intensive treatment of diabetes on the development and 
progression of long-term complications in insulin-dependent diabetes 
mellitus. N Engl J Med, 329:977–86.
Derosa G, Cicero AF, Dangelo A, et al. 2005a. Thiazolidinedione effects 
on blood pressure in diabetic patients with metabolic syndrome treated 
with glimepiride. Hypertens Res, 28:917–24.
Derosa G, Cicero AF, Gaddi A, et al. 2005b. A comparison of the effects 
of pioglitazone and rosiglitazone combined with glimepiride on pro-
thrombotic state in type 2 diabetic patients with the metabolic syndrome. 
Diabetes Res Clin Pract, 69:5–13.
Dormandy J, on behalf of the PROactive Writing Committee. 2006. 
PROactive study [letter]. Lancet, 367:26–7.
Dormandy JA, Charbonnel B, Eckland DJ, et al. 2005. PROactive investi-
gators. Secondary prevention of macrovascular events in patients with 
type 2 diabetes in the PROactive Study (PROspective pioglitAzone 
Clinical Trial In macroVascular Events): a randomised controlled trial. 
Lancet, 366:1279–89.
The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone 
Medication) Trial Investigators. 2006. Effect of rosiglitazone on the fre-
quency of diabetes in patients with impaired glucose tolerance or impaired 
fasting glucose: a randomized controlled trial. Lancet, 368:1096–105.
Emberson JR, Whincup PH, Lawlor DA, et al. 2005. Coronary heart disease 
prevention in clinical practice: are patients with diabetes special? Evi-
dence from two studies of older men and women. Heart, 91:451–5.
Erdmann E, Dormandy JA, Charbonnel B, et al; on behalf of the PROactive 
investigators. 2007. The effect of pioglitazone on recurrent myocardial 
infarction in 2445 patients with type 2 diabetes and previous myocardial 
infarction – Results from PROactive (PROactive 05). J Am Coll Cardiol, 
49:1772–80.
Erdmann E, Dormandy JA, Kupfer S, et al. 2006. Morbidity after reports 
of serious heart failure in type 2 diabetes patients with underlying 
cardiovascular disease: results from PROactive [abstract]. Circulation, 
114(Suppl 11):848.
European Diabetes Policy Group. 1998–1999. A Desktop Guide to 
Type 2 Diabetes Mellitus. Accessed 17 September 2006. URL: 
http://www.staff.ncl.ac.uk/philip.home/t2dgw97r.doc. 
Gaede P, Parving HH, Pedersen O. 2006. PROactive study. Lancet, 367:23–4.
Gaede P, Vedel P, Larsen N, et al. 2003. Multifactorial intervention and 
cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 
348:383–93.
Goldberg RB, Kendall DM, Deeg MA, et al. 2005. GLAI Study Investiga-
tors. A comparison of lipid and glycemic effects of pioglitazone and 
rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes 
Care, 28:1547–54.
Goldberg RB, Mellies MJ, Sacks FM, et al; for the Care Investigators. 1998. 
Cardiovascular events and their reduction with pravastatin in diabetic 
and glucose-intolerant myocardial infarction survivors with average 
cholesterol levels. Subgroup analyses in the cholesterol and recurrent 
events (CARE) trial. Circulation, 98:2513–9.
Haffner SM, Lehto S, Rönnemaa T, et al. 1998. Mortality from coronary 
heart disease in subjects with type 2 diabetes and in nondiabetic 
subjects with and without prior myocardial infarction. N Engl J Med, 
339:229–34.
Hanefeld M, Brunetti P, Schernthaner GH, et al. 2004. QUARTET Study 
Group. One-year glycemic control with a sulfonylurea plus pioglitazone 
versus a sulfonylurea plus metformin in patients with type 2 diabetes. 
Diabetes Care, 27:141–7.
Hansson L, Zanchetti A, Carruthers SG, et al; for the HOT Study Group. 
1998. Effects of intensive blood-pressure lowering and low-dose 
aspirin in patients with hypertension: principal results of the Hyperten-
sion Optimal Treatment (HOT) randomised trial. HOT Study Group. 
Lancet, 351:1755–62.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. 2000. 
Effects of ramipril on cardiovascular and microvascular outcomes in 
people with diabetes mellitus: results of the HOPE study and MICRO-
HOPE substudy. Lancet, 355:253–9.
Heart Protection Study Collaborative Group. 2003. MRC/BHF Heart 
Protection Study of cholesterol-lowering with simvastatin in 5963 
people with diabetes: a randomised placebo-controlled trial. Lancet, 
361:2005–16.
Heine R, Schindhelm R, Diamant M. 2006. Long-term pioglitazone treat-
ment improves markers of liver function: results from PROactive 
[Abstract]. Diabetes, 55(Suppl 1):A115.
Hollenberg NK. 2003. Considerations for management of ﬂ  uid dynamic issues 
associated with thiazolidinediones. Am J Med, 115(Suppl 8A):111S–5S.
Home PD, Pocock SJ, Beck-Nielsen H, et al. 2005. Rosiglitazone Evalu-
ated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes 
(RECORD): study design and protocol. Diabetologia, 48:1726–35.
Horio T, Suzuki M, Suzuki K, et al. 2005. Pioglitazone improves left 
ventricular diastolic function in patients with essential hypertension. 
Am J Hypertens, 18:949–57.
Idris I, Thomson GA, Sharma JC. 2006. Diabetes mellitus and stroke. 
Int J Clin Pract, 60:48–56.
Juutilainen A, Lehto S, Rönnemaa T, et al. 2005. Type 2 diabetes as a 
“coronary heart disease equivalent”: an 18-year prospective population-
based study in Finnish subjects. Diabetes Care, 28:2901–7.
Karter AJ, Ahmed AT, Liu J, et al. 2005. Pioglitazone initiation and 
subsequent hospitalization for congestive heart failure. Diabet Med, 
22:986–93.
Keech A, Simes RJ, Barter P, et al. 2005. FIELD study investigators. Effects 
of long-term fenoﬁ  brate therapy on cardiovascular events in 9795 people 
with type 2 diabetes mellitus (the FIELD study): randomised controlled 
trial. Lancet, 366:1849–61.
Ko DT, Mamdani M, Alter DA. 2004. Lipid-lowering therapy with statins 
in high-risk elderly patients: the treatment-risk paradox. JAMA, 
291:1864–70.
Langenfeld MR, Forst T, Hohberg C, et al. 2005. Pioglitazone decreases 
carotid intima-media thickness independently of glycemic control 
in patients with type 2 diabetes mellitus: results from a controlled 
randomized study. Circulation, 111:2525–31.Vascular Health and Risk Management 2007:3(4) 369
The PROactive study
Lawrence JM, Reid J, Taylor GJ, et al. 2004. Favorable effects of pioglitazone 
and metformin compared with gliclazide on lipoprotein subfractions in 
overweight patients with early type 2 diabetes. Diabetes Care, 27:41–6.
The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) 
Study Group. 1998. Prevention of cardiovascular events and death with 
pravastatin in patients with coronary heart disease and a broad range of 
initial cholesterol levels. N Engl J Med, 339:1349–57.
Marx N, Wohrle J, Nusser T, et al. 2005. Pioglitazone reduces neointima 
volume after coronary stent implantation: a randomized, placebo-
controlled, double-blind trial in nondiabetic patients. Circulation, 
112:2792–8.
Massi-Benedetti M, Scheen A, Charbonnel B. 2006. Pioglitazone delays 
the need for permanent insulin use: results from PROactive [abstract]. 
Diabetes, 55(Suppl 1):A124.
Meinert CL, Knatterud GL, Prout TE, et al. 1970. A study of the 
effects of hypoglycemic agents on vascular complications in 
patients with adult-onset diabetes. II. Mortality results. Diabetes, 
19(Suppl):789–830.
Miettinen H, Lehto S, Salomaa V, et al. 1998. Impact of diabetes on mortality 
after the ﬁ  rst myocardial infarction. The FINMONICA Myocardial 
Infarction Register Study Group. Diabetes Care, 21:69–75.
Miyazaki Y, Mahankali A, Matsuda M, et al. 2002. Effect of pioglitazone 
on abdominal fat distribution and insulin sensitivity in type 2 diabetic 
patients. J Clin Endocrinol Metab, 87:2784–91.
Miyazaki Y, Mahankali A, Wajcberg E, et al. 2004. Effect of pioglitazone 
on circulating adipocytokine levels and insulin sensitivity in type 2 
diabetic patients. J Clin Endocrinol Metab, 89:4312–9.
Mukamal KJ, Nesto RW, Cohen MC, et al. 2001. Impact of diabetes 
on long-term survival after acute myocardial infarction: compa-
rability of risk with prior myocardial infarction. Diabetes Care, 
24:1422–7.
Nathan DM, Cleary PA, Backlund JY, et al. 2005. Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and 
Complications (DCCT/EDIC) Study Research Group. Intensive diabetes 
treatment and cardiovascular disease in patients with type 1 diabetes. 
N Engl J Med, 353:2643–53.
Nathan DM, Lachin J, Cleary P, et al. 2003. Diabetes Control and 
Complications Trial; Epidemiology of Diabetes Interventions and 
Complications Research Group. Intensive diabetes therapy and 
carotid intima-media thickness in type 1 diabetes mellitus. N Engl J 
Med, 348:2294–303.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III). 2002. Third Report of the National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment 
Panel III) ﬁ  nal report. Circulation, 106:3143–421.
Nigro J, Osman N, Dart AM, et al. 2006. Insulin resistance and atheroscle-
rosis. Endocr Rev, 27:242–59. 
Nikolaidis LA, Levine TB. 2004. Peroxisome proliferator activator receptors 
(PPAR), insulin resistance, and cardiomyopathy: friends or foes for the 
diabetic patient with heart failure? Cardiol Rev, 12:158–70.
Pavo I, Jermendy G, Varkonyi TT, et al. 2003. Effect of pioglitazone 
compared with metformin on glycemic control and indicators of insulin 
sensitivity in recently diagnosed patients with type 2 diabetes. J Clin 
Endocrinol Metab, 88:1637–45.
Perez A, Khan M, Johnson T, et al. 2004. Pioglitazone plus a sulphonylurea 
or metformin is associated with increased lipoprotein particle size in 
patients with type 2 diabetes. Diab Vasc Dis Res, 1:44–50.
Pfutzner A, Marx N, Lubben G, et al. 2005. Improvement of cardiovascular 
risk markers by pioglitazone is independent from glycemic control: 
results from the pioneer study. J Am Coll Cardiol, 45:1925–31.
Pyörälä K, Pedersen TR, Kjekshus J, et al; for the Scandinavian Simvastatin 
Survival Study (4S) Group. 1997. Cholesterol lowering with simvastatin 
improves prognosis of diabetic patients with coronary heart disease. 
A subgroup analysis of the Scandinavian Simvastatin Survival Study 
(4S). Diabetes Care, 20:614–20.
Roden M, Laakso M, Johns D, et al. 2005. Long-term effects of pioglitazone 
and metformin on insulin sensitivity in patients with Type 2 diabetes 
mellitus. Diabet Med, 22:1101–6.
Roper NA, Bilous RW, Kelly WF, et al. 2001. Excess mortality in a popula-
tion with diabetes and the impact of material deprivation: longitudinal 
population based study. BMJ, 322:1389–93.
Rydén L, Thráinsdóttir I, Swedberg K. 2007. Adjudication of serious heart 
failure in patients from PROactive [letter]. Lancet, 368:189–90.
Satoh N, Ogawa Y, Usui T, et al. 2003. Antiatherogenic effect of piogli-
tazone in type 2 diabetic patients irrespective of the responsiveness to 
its antidiabetic effect. Diabetes Care, 26:2493–9.
Schaumberg DA, Glynn RJ, Jenkins AJ, et al. 2005. Effect of intensive 
glycemic control on levels of markers of inﬂ  ammation in type 1 diabetes 
mellitus in the diabetes control and complications trial. Circulation, 
111: 2446–53.
Scheen A, Charbonnel B. 2006. Reduced insulin requirements and improved 
glycaemic control with pioglitazone in insulin-treated patients with 
type 2 diabetes: results from PROactive [abstract]. Diabetes, 55(Suppl 
1):A134.
Schernthaner G, Matthews DR, Charbonnel B, et al. 2004. Quartet Study 
Group. Efﬁ  cacy and safety of pioglitazone versus metformin in patients 
with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin 
Endocrinol Metab, 89:6068–76.
Shepherd J, Blauw GJ, Murphy MB, et al. 2002. PROSPER study group. 
PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in 
elderly individuals at risk of vascular disease (PROSPER): a randomised 
controlled trial. Lancet, 360:1623–30.
Shiomi T, Tsutsui H, Hayashidani S, et al. 2002. Pioglitazone, a peroxi-
some proliferator-activated receptor-gamma agonist, attenuates left 
ventricular remodeling and failure after experimental myocardial 
infarction. Circulation, 106:3126–32.
Sobel BE, Frye R, Detre KM. 2003. Bypass Angioplasty Revascularization 
Investigation 2 Diabetes Trial. Burgeoning dilemmas in the management 
of diabetes and cardiovascular disease: rationale for the Bypass 
Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) 
Trial. Circulation, 107:636–42.
Stratton IM, Adler AI, Neil AW, et al; on behalf of the UK Prospective 
Diabetes Study Group. 2000. Association of glycaemia with macro-
vascular and microvascular complications of type 2 diabetes (UKPDS 
35): prospective observational study. BMJ, 321:405–12.
St John Sutton M, Rendell M, Dandona P, et al. 2002. A comparison of 
the effects of rosiglitazone and glyburide on cardiovascular function 
and glycemic control in patients with type 2 diabetes. Diabetes Care, 
25:2058–64.
Takagi T, Akasaka T, Yamamuro A, et al. 2000. Troglitazone reduces neo-
intimal tissue proliferation after coronary stent implantation in patients 
with non-insulin dependent diabetes mellitus: a serial intravascular 
ultrasound study. J Am Coll Cardiol, 36:1529–35.
Takagi T, Yamamuro A, Tamita K, et al. 2003. Pioglitazone reduces neo-
intimal tissue proliferation after coronary stent implantation in patients 
with type 2 diabetes mellitus: an intravascular ultrasound scanning 
study. Am Heart J, 146:E5.
Tan MH, Glazer NB, Johns DJ, et al. 2004a. Pioglitazone as monotherapy 
or in combination with sulfonylurea or metformin enhances insulin 
sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. 
Curr Med Res Opin, 20:723–8.
Tan MH, Johns DJ, Gonzalez Galvez G, et al. 2004b. GLAD Study Group. 
Effects of pioglitazone and glimepiride on glycemic control and in-
sulin sensitivity in Mexican patients with type 2 diabetes mellitus: A 
multicenter, randomized, double-blind, parallel-group trial. Clin Ther, 
26:680–93.
Tan MH, Johns DJ, Strand J, et al. 2004c. GLAC Study Group. Sustained 
effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycae-
mic control, and lipid proﬁ  les in patients with Type 2 diabetes. Diabet 
Med, 21:859–66.
Taskinen MR. 2003. Diabetic dyslipidaemia: from basic research to clinical 
practice. Diabetologia, 46:733–49.Vascular Health and Risk Management 2007:3(4) 370
Erdmann et al
UK Prospective Diabetes Study (UKPDS) Group. 1998. Intensive 
blood-glucose control with sulfonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 2 
diabetes (UKPDS 33). Lancet, 352:837–53.
UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive 
blood-glucose control with metformin on complications in overweight 
patients with type 2 diabetes (UKPDS 34). Lancet, 352:854–65.
UK Prospective Diabetes Study Group. 1998. Tight blood pressure control 
and risk of macrovascular and microvascular complications in type 2 
diabetes: UKPDS 38. BMJ, 317:703–13.
Wilcox R, Bousser M-G, Pirag V, et al. 2007. PROactive 04: Effects of 
pioglitazone in patients with type 2 diabetes with or without previous 
stroke – results from PROactive (PROspective pioglitAzone Clinical 
Trial In macroVascular Events. Stroke, 38:865–73.
Wilcox R, Kupfer S. 2006. Effects of pioglitazone on major adverse 
cardiovascular events (MACE) and myocardial infarction: results from 
PROactive [abstract]. Diabetes, 55(Suppl 1):A74.
Wynne AM, Mocanu MM, Yellon DM. 2005. Pioglitazone mimics 
preconditioning in the isolated perfused rat heart: a role for the 
prosurvival kinases PI3K and P42/44MAPK. J Cardiovasc Pharmacol, 
46:817–22.
Yki-Järvinen H. 2004. Thiazolidinediones. N Engl J Med, 351:1106–18.
Yki-Järvinen H. 2005. The PROactive study: some answers, many questions 
[commentary]. Lancet, 366:1241–2.
Zuanetti G, Latini R, Maggioni AP, et al. 1997. Effect of the ACE 
inhibitor lisinopril on mortality in diabetic patients with acute 
myocardial infarction. Data from the GISSI-3 study. Circulation, 
96:4239–45.